Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0PDZUJ |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | cBR96 |
|||||
| Antigen Name | Lewis Y |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
SGN-15 [Phase 2 (discontinued)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must have histologically confirmed metastatic/unresectable recurrent breast carcinoma with ≤2 prior chemotherapy regimens for metastatic disease or recurrence within 6 months post-adjuvant therapy, measurable disease/bone markers (2×ULN) with Lewis-y antigen expression, and no active brain metastases.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00028483 | Clinical Status | PHASE2 | ||
| Clinical Description |
A Phase II Study Using SGN-15 (cBR96 - Doxorubicin Immunoconjugate) in Combination With Taxotere for the Treatment of Metastatic or Recurrent Breast Carcinoma
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Patients Enrolled |
The study included patients with metastatic or recurrent NSCLC who failed 1-2 prior therapies or recurred within 6 months post-adjuvant chemo, requiring Lewis-y antigen expression and measurable/evaluable disease with ECOG ≤2 and ≥3-month life expectancy, excluding those with prior docetaxel, high anthracycline exposure, active infections, uncontrolled comorbidities, or CNS metastases.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00051571 | Clinical Status | PHASE2 | ||
| Clinical Description |
A Phase II Study Using SGN-15 (cBR96-Doxorubicin Immunoconjugate) in Combination With Docetaxel for the Treatment of Advanced Stage or Recurrent Non-Small Cell Lung Carcinoma
|
||||
| Experiment 3 Reporting the Activity Date of This ADC | [3] | ||||
| Patients Enrolled |
Eligible patients had pathologically confirmed stage IIIB/IV NSCLC with ≥1 measurable lesion, no prior metastatic chemotherapy, ECOG ≤2, available tumor block for LeY antigen testing, approved FDG-PET, and adequate organ function, excluding candidates for curative combined therapy.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00086333 | Clinical Status | PHASE2 | ||
| Clinical Description |
A Phase II Study Using FDG-PET to Investigate the Dosing Schedule and Response of Combination SGN-15 (cBR96-Doxorubicin Immunoconjugate) and Docetaxel in Patients With Stage IV or Stage IIIB Non-Small Cell Lung Carcinoma Ineligible for Combined Modality Treatment With Curative Intent
|
||||
| Experiment 4 Reporting the Activity Date of This ADC | [4] | ||||
| Patients Enrolled |
Eligible patients had pathologically confirmed advanced/recurrent ovarian cancer with 2-3 prior therapy failures, ≥20% Lewis-y antigen expression, LVEF>50%, and platinum resistance (progression during/first 6 months post-treatment).
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00051584 | Clinical Status | PHASE2 | ||
| Clinical Description |
A Phase II Study of SGN-15 (cBR96 - Doxorubicin Immunoconjugate) Combined With Gemzar® Versus Single-Agent Gemzar® in Patients With Advanced Ovarian Cancer
|
||||
| Experiment 5 Reporting the Activity Date of This ADC | [5] | ||||
| Patients Enrolled |
Eligible patients had hormone-refractory prostate cancer with disease progression evidenced by tumor growth or rising PSA with metastatic disease, plus documented Lewis (Y) antigen expression via immunohistochemistry on tumor samples.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT00031187 | Clinical Status | PHASE2 | ||
| Clinical Description |
Phase II Study of SGN-15 (cBR96 - Doxorubicin Immunoconjugate) Combined With Taxotere in Patients With Hormone Refractory Prostate Carcinoma
|
||||
References